Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-17 of 17 for your search:
Cancer Type:
Thyroid cancer
Stage/Subtype of Cancer:
stage IV papillary thyroid cancer
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MDA-2004-0059
, 6132, NCI-6132, NCT00104871
2.
17-AAG in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MAYO-MC0476
, 6482, NCI-6482, NCT00118248, JHOC-JS0652, JHOC-B/06/174
3.
Sunitinib in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
UCCRC-14696A
, 14696A, 7735, NCI-7735, NCT00381641
4.
Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
A4061027
, NCT00389441
5.
Sunitinib and Imaging Procedures in Treating Patients With Thyroid Cancer
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Diagnostic, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
UWCC-6494
, UWCC-UW 6494, UWCC- 07-6030-H/B, 6494, PFIZER-UWCC-6494, NCT00519896
6.
AZD6244 in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MCC-15305
, MCC-15305, MCC-LOI-7918, 7918, NCT00559949
7.
Sorafenib in Treating Patients With Metastatic or Unresectable Resistant Thyroid Cancer
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Not specified
Sponsor:
NCI
Protocol IDs:
UPCC-03305
, UPCC#03305, UPCC-802861, NCT00601783
8.
Pazopanib in Treating Patients With Advanced Thyroid Cancer
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MAYO-MC057H
, MC057H, 7627, NCT00625846
9.
Sutent Adjunctive Treatment of Differentiated Thyroid Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
WCI-2007-214
, NCT00668811
10.
Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
802861
, UPCC 03305, NCT00654238
11.
Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine therapy
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
MSKCC-08066
, 08-066, 7508, NCT00729157
12.
Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0047
, NCI-P6880, NCT00436735
13.
Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
04-116
, NCT00673010
14.
Vaccine Therapy in Treating Patients With Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-09-C-0101
, 09-C-0101, NCI-P08446, 8187, NCT00887016
15.
Iodine I 131 in Treating Patients With Thyroid Cancer
Phase:
No phase specified
Type:
Diagnostic, Treatment
Status:
Active
Age:
18 to 100
Sponsor:
NCI
Protocol IDs:
JHOC-J0628
, NCT00416949
16.
A Proof-of-Concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis
Phase:
No phase specified
Type:
Diagnostic, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
GE-135-003
, NCT00565721
17.
A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoind and Peroxisome-Proliferator-Activated Receptor (PPARy) Expression
Phase:
No phase specified
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
COMIRB# 07-0727
, NCT00718770
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute